VTV Therapeutics Inc-CL A (NASDAQ:VTVT) Reports Wider Q2 2025 Loss Amid Clinical-Stage Progress

VTV THERAPEUTICS INC-CL A (NASDAQ:VTVT [https://www.chartmill.com/stock/quote/VTVT/profile]) reported its second-quarter 2025 financial results, posting a net loss per share of $0.92, which was wider than the analyst consensus estimate of a $0.8415 loss. Revenue for the quarter came in at $0, matching expectations. The company’s lack of revenue reflects its clinical-stage status, with no commercialized products currently generating sales.

KEY FINANCIAL TAKEAWAYS

* EARNINGS MISS: The reported EPS of -$0.92 was approximately 9.3% worse than the estimated -$0.8415.
* REVENUE IN LINE: No revenue was recorded, consistent with analyst projections.
* CASH BURN CONTINUES: As a pre-revenue biotech firm, vTv remains reliant on funding to advance its pipeline.

MARKET REACTION

Following the earnings release, shares of vTv Therapeutics saw a modest after-hours gain of 3.52%, suggesting that investors may be looking past the wider-than-expected loss and focusing instead on clinical progress. Over the past month, the stock has been relatively stable, with a slight decline of 2.75%, while the two-week performance shows a more pronounced drop of 14.9%. The immediate uptick post-earnings could indicate cautious optimism around the company’s ongoing trials.

CORPORATE UPDATE HIGHLIGHTS

The press release emphasized progress in the company’s lead candidate, CADISEGLIATIN (TTP399), a potential adjunctive therapy for type 1 diabetes:

* The first participant has been randomized in the PHASE 3 CATT1 TRIAL, with data expected in the second half of 2026.
* No revenue-generating milestones were announced, keeping the focus on clinical development rather than near-term commercialization.

LOOKING AHEAD

Analysts expect vTv to continue posting losses, with full-year 2025 EPS projected at -$3.6414 and no sales anticipated. For Q3 2025, the consensus EPS estimate stands at -$0.918, again with zero revenue expected. The lack of a revenue outlook in the press release does not alter expectations, as the company’s valuation remains tied to clinical trial outcomes rather than near-term financial performance.

For a deeper dive into vTv Therapeutics’ earnings and estimates, visit the earnings page [https://www.chartmill.com/stock/quote/VTVT/earnings-estimates].

_Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making decisions._